BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16087843)

  • 1. Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice.
    Tolleson WH; Doss JC; Latendresse J; Warbritton AR; Melchior WB; Chin L; Dubielzig RR; Albert DM
    Arch Ophthalmol; 2005 Aug; 123(8):1088-94. PubMed ID: 16087843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of uveal amelanotic melanoma in transgenic Tyr-HRAS+ Ink4a/Arf heterozygous mice.
    Latendresse JR; Muskhelishvili L; Warbritton A; Tolleson WH
    Toxicol Pathol; 2007 Oct; 35(6):827-32. PubMed ID: 17987514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
    Ackermann J; Frutschi M; Kaloulis K; McKee T; Trumpp A; Beermann F
    Cancer Res; 2005 May; 65(10):4005-11. PubMed ID: 15899789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.
    Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS
    Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
    Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
    Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
    Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
    Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strategy to study tyrosinase transgenes in mouse melanocytes.
    Lavado A; Matheu A; Serrano M; Montoliu L
    BMC Cell Biol; 2005 Apr; 6(1):18. PubMed ID: 15826307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.
    Yang J; Luan J; Yu Y; Li C; DePinho RA; Chin L; Richmond A
    Cancer Res; 2001 Nov; 61(22):8150-7. PubMed ID: 11719444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
    van der Velden PA; Metzelaar-Blok JA; Bergman W; Monique H; Hurks H; Frants RR; Gruis NA; Jager MJ
    Cancer Res; 2001 Jul; 61(13):5303-6. PubMed ID: 11431374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inducible mouse model of melanoma expressing a defined tumor antigen.
    Huijbers IJ; Krimpenfort P; Chomez P; van der Valk MA; Song JY; Inderberg-Suso EM; Schmitt-Verhulst AM; Berns A; Van den Eynde BJ
    Cancer Res; 2006 Mar; 66(6):3278-86. PubMed ID: 16540681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
    Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
    Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma.
    O'Hagan RC; Brennan CW; Strahs A; Zhang X; Kannan K; Donovan M; Cauwels C; Sharpless NE; Wong WH; Chin L
    Cancer Res; 2003 Sep; 63(17):5352-6. PubMed ID: 14500367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The INK4a/ARF locus and melanoma.
    Sharpless E; Chin L
    Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
    Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase.
    Cohen-Solal KA; Reuhl KR; Ryan KB; Roberts KG; Chen S
    Pigment Cell Res; 2001 Dec; 14(6):466-74. PubMed ID: 11775059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis.
    Uhrbom L; Kastemar M; Johansson FK; Westermark B; Holland EC
    Cancer Res; 2005 Mar; 65(6):2065-9. PubMed ID: 15781613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures.
    van Schanke A; van Venrooij GM; Jongsma MJ; Banus HA; Mullenders LH; van Kranen HJ; de Gruijl FR
    Cancer Res; 2006 Mar; 66(5):2608-15. PubMed ID: 16510579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.